Real-world data of first-line treatment with aumolertinib for elderly EGFR plus NSCLC patients

被引：0
|
作者：
Zhang, H. [1 ]
Cun, F. S. [1 ]
机构：
[1] Nanjing Chest Hosp, Resp Med, Nanjing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.409
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
371P
引用
收藏
页码：S1586 / S1587
页数：2
相关论文
共 50 条
  • [31] Treatment patterns of EGFR mt plus NSCLC IV pts: Real-world data of the NOWEL network
    Roeper, J.
    Falk, M.
    Schatz, S.
    Tiemann, M.
    Wesseler, C.
    Wiest, G. H.
    Sackmann, S.
    Ukena, D.
    Griesinger, F.
    ANNALS OF ONCOLOGY, 2019, 30 : 630 - 630
  • [32] Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients
    Shen, B.
    Pan, B.
    Wu, Y.
    Shi, L.
    Gao, J.
    Du, X.
    Feng, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S317 - S318
  • [33] START: Real-world Prospective Study on Sequential Therapy with First-Line Afatinib in Chinese Patients with EGFRm plus Advanced NSCLC
    Zhou, J.
    Xue, Z.
    Li, Q.
    Ling, X.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S632 - S633
  • [34] Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): A randomized multicenter study
    Hu, Y.
    Zhang, F.
    Zhao, M.
    Zheng, Z.
    Zhang, H.
    Jiang, T.
    Liu, Z.
    Wen, J.
    Gan, X.
    Wang, H.
    Wu, L.
    Cang, S.
    Zhao, J.
    Li, X.
    Peng, L.
    Fan, Z.
    Shen, G.
    Zhou, Q.
    Zou, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1312 - S1312
  • [35] Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data
    Passaro, Antonio
    Pochesci, Alessia
    Spitaleri, Gianluca
    Catania, Chiara
    Noberasco, Cristina
    Del Signore, Ester
    de Marinis, Filippo
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (10) : 1283 - 1288
  • [36] Optimal first-line chemotherapy for the elderly with metastatic colorectal cancer, based on the real-world data
    Sugimura, N.
    Shimura, T.
    Fukusada, S.
    Tanaka, M.
    Kataoka, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1446 - S1446
  • [37] Real-World Treatment Patterns, Healthcare Cost and Resource Utilization in First-Line Treatment of Metastatic NSCLC in the US
    Chopra, D.
    Waterhouse, D. M.
    Sultan, I.
    Lonshteyn, A.
    Delea, T. E.
    Stollenwerk, B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S400 - S401
  • [38] Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC
    Saw, Stephanie Pei Li
    Low, Yi Fen
    Lai, Gillianne
    Chan, Landon
    Wong, Wesley K. Y.
    Tsui, Giselle
    Chen, Olivia
    Seet, Amanda Oon Lim
    Tan, Wei Chong
    Tan, Aaron C.
    Chan, Johan W. K.
    Teh, Yi Lin
    Tan, Wan Ling
    Ng, Quan Sing
    Ang, Mei-Kim
    Kanesvaran, Ravindran
    Lim, Darren Wan-Teck
    Tan, Daniel Shao-Weng
    Mok, Tony S. K.
    Li, Molly Sc
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC
    Saw, Stephanie P. L.
    Low, Yi Fen
    Lai, Gillianne G. Y.
    Chan, Landon L.
    Wong, Wesley K. Y.
    Tsui, Giselle
    Chen, Olivia H.
    Seet, Amanda O. L.
    Tan, Wei Chong
    Tan, Aaron C.
    Chan, Johan W. K.
    Teh, Yi Lin
    Tan, Wan -Ling
    Ng, Quan Sing
    Ang, Mei-Kim
    Kanesvaran, Ravindran
    Lim, Darren W. T.
    Tan, Daniel S. W.
    Mok, Tony S. K.
    Li, Molly S. C.
    LUNG CANCER, 2024, 193
  • [40] Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
    Zhou, J.
    Shen, L.
    Lv, D.
    Tang, K.
    Zhu, D.
    Zhao, Y.
    Wang, K.
    Wang, Y.
    Xing, L.
    Cui, J.
    Ding, L.
    Shi, X.
    Zheng, J.
    Zhou, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1689 - S1690
12345